0001357878
false
0001357878
2026-05-06
2026-05-06
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
xbrli:pure
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported): May 6, 2026
REGENEREX PHARMA, INC
(Exact Name of Registrant as Specified in its Charter)
Nevada |
|
000-53230 |
|
98-0479983 |
(State or Other Jurisdiction of Incorporation) |
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
5348 Vegas Drive #177 Las Vegas, NV |
|
89108 |
(Address of Principal Executive Offices) |
|
(Zip Code) |
Registrant’s telephone number, including area
code: (877) 761-7479
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2.
below):
|
[ ] |
Written communications pursuant to Rule 425 under
the Securities Act (17 CFR 230.425) |
|
[ ] |
Soliciting material pursuant to Rule 14a-12 under
the Exchange Act (17 CFR 240.14a-12) |
|
[ ] |
Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
[ ] |
Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e 4(c)) |
Securities registered pursuant to Section
12(b) of the Act: None.
Indicate by check mark whether the registrant is an
emerging growth company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of
1934 (§240.12b-2 of this chapter).
Emerging
growth company [X]
If
an emerging growth company, indicate by check mark if the registrant has
elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section
13(a) of the Exchange Act. [ ]
Item 5.02 – Departure of Directors or
Certain Officers; Appointment of Certain Officers; Compensatory Arrangements of
Certain Officers
Mr. Kenneth Perry Chief Financial
Officer was placed on administrative suspension with pay effective March 31,
2026. Following the Committee’s review and recommendation, the Independent
Board of Directors approved the termination of Mr. Perry’s employment for
Cause, with notice of such termination delivered on May 2, 2026.
On April 27, 2026 the Board of
Directors (the “Board”) of (the “Company”), acting upon the recommendation of
its Governance and Nominating Committee (the “Committee”), determined that the
conduct of the Company’s Chief Financial Officer, Kenneth Perry, constituted a
material and continuing breach of his Employment Agreement and satisfied the
definition of “Cause” as set forth therein.
The Committee, which is comprised of three
independent advisors, conducted a comprehensive review of relevant materials,
including audit-related findings, Board records, and documented communications.
Upon completion of its review, the Committee submitted its findings and formal
recommendation to the independent members of the Board. A meeting of the
independent members of the Board was held on April 27, 2026, at which two of
the three directors were present. The Company’s Chief Executive Officer recused
himself from all deliberations and decisions related to this matter.
In connection with the foregoing, on April 1, 2026,
the Board appointed Don E. Ray to serve as Interim Chief Financial Officer of
the Company. Mr. Ray’s appointment is for an initial term of 90 days.
Contact:
Regenerex Pharma, Inc.
Company
Ph: 877-761-RGPX (7479)
Investor
Relations Ph: (305) 927-5191
Email:
investors@regenerexpharmainc.com
regenerexpharmainc.com
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this Report to be signed on its behalf by the undersigned, hereunto
duly authorized.
|
REGENEREX PHARMA, INC. |
|
|
|
|
By: |
/s/ Greg
Pilant |
Date: May 6,
2026 |
Name: |
Greg Pilant |
|
Title: |
Chief Executive
Officer |
